Achillion Pharmaceuticals CEO Michael Kishbauch told Bloomberg that his drug development group has entered serious talks with potential partners and parties interested in buying his company, with the firm's board of directors preferring the latter. "We're prepared to be patient and pick the best deal," he told the news service. The firm's lead drug ACH-1625 is in mid-stage development for hepatitis C virus. Article